AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (her2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies için istatistikler